Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6310
+0.0334 (5.59%)
Mar 12, 2026, 1:55 PM EDT - Market open

Vistagen Therapeutics Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
0.910.491.06-0.231.111.09
Revenue Growth (YoY)
31.02%-54.32%--1.78%-
Gross Profit
0.910.491.06-0.231.111.09
Selling, General & Admin
12.9317.0814.0614.6613.487.1
Research & Development
38.3539.3820.0244.3835.4111.93
Total Operating Expenses
51.2856.4634.0959.0448.8919.02
Operating Income
-50.36-55.97-33.02-59.27-47.78-17.93
Interest Income
2.844.563.350.030.020
Other Non-Operating Income (Expense)
00.010.31--0
Total Non-Operating Income (Expense)
2.854.563.660.030.020
Pretax Income
-47.42-51.41-29.36-59.24-47.76-17.93
Provision for Income Taxes
--0.01-0-0.01-0-0
Net Income
-67.05-51.42-29.36-59.24-48.71-42.32
Net Income Attributable to Preferred Dividends
----0.9524.39
Net Income to Common
-67.05-51.42-29.36-59.24-48.71-42.32
Shares Outstanding (Basic)
353119773
Shares Outstanding (Diluted)
353119773
Shares Change (YoY)
15.52%59.53%178.13%5.45%129.85%96.34%
EPS (Basic)
-1.90-1.67-1.52-8.51-7.38-14.70
EPS (Diluted)
-1.90-1.67-1.52-8.51-7.38-14.70
Free Cash Flow
-60.54-42.29-25.87-49.93-45.46-12.35
Free Cash Flow Per Share
-1.71-1.37-1.34-7.17-6.89-4.30
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-8285.28%-11517.08%-3103.48%26109.25%-4308.68%-1646.06%
Profit Margin
-10964.19%-10579.84%-2759.59%26095.15%-4306.57%-1645.62%
FCF Margin
-9899.75%-8701.23%-2431.77%21994.71%-4099.28%-1133.45%
EBITDA
-50.48-55.82-32.89-59.14-47.63-17.82
EBITDA Margin
-8254.70%-11486.21%-3091.54%26051.98%-4294.83%-1635.26%
EBIT
-50.36-55.97-33.02-59.27-47.78-17.93
EBIT Margin
-8285.28%-11517.08%-3103.48%26109.25%-4308.68%-1646.06%
Effective Tax Rate
-0.01%0.01%0.01%0.01%0.01%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q